[go: up one dir, main page]

AR103182A1 - Inmunomoduladores - Google Patents

Inmunomoduladores

Info

Publication number
AR103182A1
AR103182A1 ARP150104203A ARP150104203A AR103182A1 AR 103182 A1 AR103182 A1 AR 103182A1 AR P150104203 A ARP150104203 A AR P150104203A AR P150104203 A ARP150104203 A AR P150104203A AR 103182 A1 AR103182 A1 AR 103182A1
Authority
AR
Argentina
Prior art keywords
ring
hydrogen
methyl
independently selected
optionally substituted
Prior art date
Application number
ARP150104203A
Other languages
English (en)
Inventor
Michael Scola Paul
Mull Eric
Patrick Allen Martin
Matthew Miller Michael
P Gillis Eric
Zhao Qian
Sun Li-Qiang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR103182A1 publication Critical patent/AR103182A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Proporciona péptidos macrocíclicos que inhiben las interacciones proteína/proteína PPD-1/PD-L1 y PD-L1/CD80, y por ende, son útiles para la mejora de varias enfermedades, que incluyen el cáncer y las enfermedades infecciosas. Reivindicación 1: Un compuesto, caracterizado porque tiene la fórmula (1), o una sal de este aceptable desde el punto de vista farmacéutico, en donde: A se selecciona de un enlace, o un compuesto del grupo de fórmulas (2); en donde: la línea ondulada * indica el punto de unión al grupo carbonilo y la línea ondulada indica el punto de unión al átomo de nitrógeno; z es 0, 1 ó 2; w es 1 ó 2; n es 0 ó 1; m es 1 ó 2; m es 0 ó 1; p es 0, 1 ó 2; Rˣ se selecciona de hidrógeno, amino, hidroxi y metilo; R¹⁴ y R¹⁵ se seleccionan independientemente de hidrógeno y metilo; y Rᶻ se selecciona de hidrógeno y -C(O)NHR¹⁶; en donde R¹⁶ se selecciona de hidrógeno, -CHR¹⁷C(O)NH₂, -CHR¹⁷C(O)NHCHR¹⁸C(O)NH₂ y -CHR¹⁷C(O)NHCHR¹⁸C(O)NHCH₂C(O)NH₂; en donde R¹⁷ se selecciona de hidrógeno y -CH₂OH, y en donde R¹⁸ se selecciona de hidrógeno y metilo; Rᵛ es hidrógeno o una cadena lateral de aminoácido natural; Rᶜ, Rᶠ, Rʰ, Rⁱ y Rᵐ son hidrógeno; Rⁿ es hidrógeno o metilo, o Rᵛ y Rⁿ forman un anillo de pirrolidina; Rᵃ, Rᵉ, Rʲ y Rᵏ se seleccionan independientemente de hidrógeno y metilo; cada R²⁰ se selecciona independientemente de hidrógeno y C₁₋₆alquilo; cada R²¹ se selecciona independientemente de hidrógeno y C₁₋₆alquilo; R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹² y R¹³ se seleccionan independientemente de una cadena lateral de aminoácido natural y una cadena lateral de aminoácido no natural, o cada uno puede formar independientemente un anillo carbocíclico de tres a seis miembros o un anillo de seis miembros que contiene un átomo de oxígeno o de nitrógeno con un grupo R²⁰ germinal correspondiente, en donde el anillo se sustituye opcionalmente con uno, dos o tres sustituyentes seleccionados independientemente de C₁₋₃alcoxi, C₁₋₃alquilo, C₂₋₄alquenilo, halo, hidroxi y amino y en donde el anillo de cinco y seis miembros se fusiona opcionalmente a un anillo de fenilo; o R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹² y R¹³ pueden formar, cada uno independientemente, un anillo con el grupo R próximo correspondiente como se describe más adelante; Rᵉ y Rᵏ pueden formar, cada uno, un anillo con el grupo R próximo correspondiente y los átomos a los que están unidos, seleccionado de azetidina, pirrolidina, morfolina, piperidina, piperazina y tetrahidrotiazol; en donde cada anillo se sustituye opcionalmente con uno a cuatro grupos seleccionados independientemente de amino, ciano, metilo, halo e hidroxi; Rᵇ es metilo, o Rᵇ y R², junto con los átomos a los que están unidos, forman un anillo seleccionado de azetidina, pirrolidina, morfolina, piperidina, piperazina y tetrahidrotiazol; en donde cada anillo se sustituye opcionalmente con uno a cuatro grupos seleccionados independientemente de amino, ciano, metilo, halo e hidroxi; o cuando R² y el R²⁰ germinal no son hidrógeno, Rᵇ es hidrógeno; Rᵈ es hidrógeno o metilo, o Rᵈ y R⁴, junto con los átomos a los que están unidos, pueden formar un anillo seleccionado de azetidina, pirrolidina, morfolina, piperidina, piperazina y tetrahidrotiazol; en donde cada anillo se sustituye opcionalmente con uno a cuatro grupos seleccionados independientemente de amino, ciano, metilo, halo, hidroxi y fenilo; Rᵍ es hidrógeno o metilo, o Rᵍ y R⁷, junto con los átomos a los que están unidos, pueden formar un anillo seleccionado de azetidina, pirrolidina, morfolina, piperidina, piperazina y tetrahidrotiazol; en donde cada anillo se sustituye opcionalmente con uno a cuatro grupos seleccionados independientemente de amino, bencilo opcionalmente sustituido con un grupo halo, bencìloxi, ciano, ciclohexilo, metilo, halo, hidroxi, isoquinoliniloxi opcionalmente sustituido con un grupo metoxi, quinoliniloxi opcionalmente sustituido con un grupo halo, y tetrazolilo; y en donde los anillos de pirrolidina y piperidina están opcionalmente fusionados con un grupo ciclohexilo, fenilo o indol; y Rˡ es metilo, o Rˡ y R¹², junto con los átomos a los que están unidos, forman un anillo seleccionado de azetidina y pirrolidina, en donde cada anillo se sustituye opcionalmente con uno a cuatro grupos seleccionados independientemente de amino, ciano, metilo, halo e hidroxi; siempre que el compuesto de la fórmula (1) contenga al menos un carbono en la estructura principal del anillo que tiene cuatro sustituyentes que no son hidrógeno y no es un anillo sustituido con a-metilo.
ARP150104203A 2014-12-19 2015-12-18 Inmunomoduladores AR103182A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462094281P 2014-12-19 2014-12-19

Publications (1)

Publication Number Publication Date
AR103182A1 true AR103182A1 (es) 2017-04-19

Family

ID=55071225

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150104203A AR103182A1 (es) 2014-12-19 2015-12-18 Inmunomoduladores

Country Status (27)

Country Link
US (1) US9944678B2 (es)
EP (1) EP3233887B1 (es)
JP (1) JP6705823B2 (es)
KR (1) KR102590776B1 (es)
CN (1) CN107223129B (es)
AR (1) AR103182A1 (es)
AU (1) AU2015364573A1 (es)
BR (1) BR112017012704A2 (es)
CA (1) CA2971266A1 (es)
CY (1) CY1121571T1 (es)
DK (1) DK3233887T3 (es)
EA (1) EA033721B1 (es)
ES (1) ES2719135T3 (es)
HR (1) HRP20190575T1 (es)
HU (1) HUE044027T2 (es)
IL (1) IL252896A0 (es)
LT (1) LT3233887T (es)
MX (1) MX2017008160A (es)
PL (1) PL3233887T3 (es)
PT (1) PT3233887T (es)
RS (1) RS58580B1 (es)
SG (1) SG11201704821VA (es)
SI (1) SI3233887T1 (es)
SM (1) SMT201900253T1 (es)
TR (1) TR201906470T4 (es)
TW (1) TW201629087A (es)
WO (1) WO2016100608A1 (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015007051A (es) 2012-12-07 2016-01-12 Chemocentryx Inc Diazol lactamas.
ES2768610T3 (es) 2014-09-11 2020-06-23 Bristol Myers Squibb Co Inhibidores macrocíclicos de las interacciones proteína/proteína PD-1/PD-L1 y CD80(B7-1)/PD-L1
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
MA42133A (fr) 2015-05-21 2021-06-02 Chemocentryx Inc Modulateurs du ccr2
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) * 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
TWI808938B (zh) 2016-04-07 2023-07-21 美商卡默森屈有限公司 藉由投予ccr1拮抗劑與pd-1抑制劑或pd-l1抑制劑之組合減少腫瘤負荷
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2017201111A1 (en) 2016-05-19 2017-11-23 Bristol-Myers Squibb Company Pet-imaging immunomodulators
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
CN110267971B (zh) * 2016-11-07 2023-12-19 百时美施贵宝公司 免疫调节剂
IL267572B2 (en) 2016-12-23 2025-02-01 Univ Johns Hopkins Tumor and immune cell imaging based on PD-L1 expression
US20190336533A1 (en) 2016-12-28 2019-11-07 Green Cross Lab Cell Corporation Chimeric antigen receptor and natural killer cells expressing same
JP7206222B2 (ja) * 2017-06-23 2023-01-17 ブリストル-マイヤーズ スクイブ カンパニー Pd-1のアンタゴニストとして作用する免疫調節剤
BR112020005284A2 (pt) 2017-09-25 2020-09-24 Chemocentryx, Inc. terapia de combinação usando um antagonista do receptor de quimiocina 2 (ccr2) e um inibidor de pd-1/pd-l1
WO2019070643A1 (en) * 2017-10-03 2019-04-11 Bristol-Myers Squibb Company IMMUNOMODULATORS
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
EP3712178A4 (en) 2017-11-14 2021-08-11 Green Cross Lab Cell Corporation ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
IL275898B2 (en) 2018-01-08 2025-05-01 Chemocentryx Inc Methods for treating solid tumors with CCR2 antagonists
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
AU2019277632A1 (en) 2018-05-31 2020-12-24 National Cancer Center Japan Biomarker for judging efficacy of immune checkpoint inhibitor
TW202017569A (zh) 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
TW202446772A (zh) 2018-10-11 2024-12-01 日商小野藥品工業股份有限公司 Sting促效化合物
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
CN113543851B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US20220195046A1 (en) 2019-03-28 2022-06-23 Bristol-Myers Squibb Company Methods of treating tumor
CN113677402A (zh) 2019-03-28 2021-11-19 百时美施贵宝公司 治疗肿瘤的方法
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
KR20220010535A (ko) * 2019-05-21 2022-01-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
KR20220016157A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 조합 요법
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
JP2022534967A (ja) 2019-05-30 2022-08-04 ブリストル-マイヤーズ スクイブ カンパニー 多腫瘍遺伝子シグネチャーおよびその使用
JP7662156B2 (ja) 2019-08-05 2025-04-15 小野薬品工業株式会社 免疫チェックポイント阻害薬の有効性判定バイオマーカー
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CN114450028A (zh) 2019-09-22 2022-05-06 百时美施贵宝公司 Lag-3拮抗剂治疗的定量空间剖析
CA3149557A1 (en) 2019-09-30 2021-04-08 Scott J. Balsitis Hbv vaccines and methods treating hbv
US12404299B2 (en) 2019-11-07 2025-09-02 Chugai Seiyaku Kabushiki Kaisha Method for producing peptide compound comprising highly sterically hindered amino acid
CA3159931A1 (en) * 2019-11-07 2021-05-14 Chugai Seiyaku Kabushiki Kaisha Cyclic peptide compound having kras inhibitory action
JP2022553851A (ja) 2019-11-08 2022-12-26 ブリストル-マイヤーズ スクイブ カンパニー 黒色腫の処置のためのlag-3アンタゴニスト
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US12403174B2 (en) 2020-01-06 2025-09-02 Bristol-Myers Squibb Company Immunomodulators
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
KR20220161407A (ko) 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
WO2021205631A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 Sting作動化合物
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
CN113754736A (zh) * 2020-06-02 2021-12-07 南京礼威生物医药有限公司 含酰肼结构的pd-l1环肽抑制剂
AU2021331476A1 (en) 2020-08-28 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
US20230303700A1 (en) 2020-08-31 2023-09-28 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022066635A1 (en) 2020-09-22 2022-03-31 Avidea Technologies, Inc. Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
MX2023004493A (es) 2020-10-23 2023-05-10 Bristol Myers Squibb Co Terapia de agonista del gen-3 de activacion del linfocito (lag-3) para cancer de pulmon.
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022212400A1 (en) 2021-03-29 2022-10-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
AR125800A1 (es) 2021-05-07 2023-08-16 Chugai Pharmaceutical Co Ltd Métodos para producir compuestos cíclicos que comprendan residuos de aminoácidos sustituidos con n
AU2022270499A1 (en) * 2021-05-07 2023-11-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical use of cyclic peptide compound
JP2024518558A (ja) 2021-05-13 2024-05-01 ギリアード サイエンシーズ, インコーポレイテッド TLR8調節化合物と抗HBV siRNA治療薬との組合せ
JP2024520801A (ja) 2021-06-11 2024-05-24 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
CA3222752A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022375806A1 (en) 2021-10-29 2023-12-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
JP2025503962A (ja) 2022-01-26 2025-02-06 ブリストル-マイヤーズ スクイブ カンパニー 肝細胞がんのための併用療法
US20230326022A1 (en) 2022-04-08 2023-10-12 Bristol-Myers Squibb Company Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures
IL318949A (en) 2022-08-23 2025-04-01 Ono Pharmaceutical Co Bispecific antibody
KR20250123912A (ko) 2022-12-21 2025-08-18 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 병용 요법
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025193572A1 (en) * 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Pd−1に対する抗体およびその使用
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP3012265B1 (en) 2007-03-26 2017-06-28 The University of Tokyo Process for synthesizing cyclic peptide compound
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 N−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
EP2647720B1 (en) 2010-12-03 2019-06-19 The University of Tokyo Peptide library production method, peptide library, and screening method
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
EP2822957A1 (en) * 2012-03-07 2015-01-14 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
AU2013239366A1 (en) 2012-03-29 2014-10-16 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the BC loop of human PD1
MX355396B (es) 2012-06-06 2018-04-18 Polyphor Ag Peptido - mimeticos de la horquilla beta.
WO2013182662A1 (en) * 2012-06-06 2013-12-12 Bionor Immuno As Vaccine
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo pH依存的に標的分子に結合するペプチドのスクリーニング方法
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
AU2014235453A1 (en) 2013-03-15 2015-10-08 Genentech, Inc. Biomarkers and methods of treating PD-1 and PD-L1 related conditions
CA2922982A1 (en) 2013-09-06 2015-03-12 Aurigene Discovery Technologies Limited Cyclic peptidomimetic compounds as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
ES2768610T3 (es) 2014-09-11 2020-06-23 Bristol Myers Squibb Co Inhibidores macrocíclicos de las interacciones proteína/proteína PD-1/PD-L1 y CD80(B7-1)/PD-L1
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) * 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators

Also Published As

Publication number Publication date
US9944678B2 (en) 2018-04-17
US20160176928A1 (en) 2016-06-23
EP3233887A1 (en) 2017-10-25
CA2971266A1 (en) 2016-06-23
JP2018504378A (ja) 2018-02-15
TW201629087A (zh) 2016-08-16
PL3233887T3 (pl) 2019-08-30
KR102590776B1 (ko) 2023-10-18
MX2017008160A (es) 2017-09-18
AU2015364573A1 (en) 2017-08-03
HUE044027T2 (hu) 2019-09-30
CN107223129A (zh) 2017-09-29
LT3233887T (lt) 2019-04-25
BR112017012704A2 (pt) 2018-03-06
IL252896A0 (en) 2017-08-31
ES2719135T3 (es) 2019-07-08
SI3233887T1 (sl) 2019-04-30
RS58580B1 (sr) 2019-05-31
CN107223129B (zh) 2022-01-04
JP6705823B2 (ja) 2020-06-03
PT3233887T (pt) 2019-04-30
DK3233887T3 (da) 2019-05-13
KR20170098872A (ko) 2017-08-30
EP3233887B1 (en) 2019-02-06
EA033721B1 (ru) 2019-11-20
SMT201900253T1 (it) 2019-07-11
EA201791216A1 (ru) 2017-10-31
HRP20190575T1 (hr) 2019-05-17
CY1121571T1 (el) 2020-05-29
WO2016100608A1 (en) 2016-06-23
TR201906470T4 (tr) 2019-05-21
SG11201704821VA (en) 2017-07-28

Similar Documents

Publication Publication Date Title
AR103182A1 (es) Inmunomoduladores
AR103093A1 (es) Péptidos macrocíclicos que inhiben interacciones proteína / proteína de proteína de la muerte (pd-1 / pd-l1) e inhiben interacción cd80 / pd-l1
AR107802A1 (es) Inmunomoduladores
AR103969A1 (es) Inmunomoduladores
AR108186A1 (es) Péptidos macrocíclicos que inhiben las interacciones proteína / proteína, proteína de muerte programada 1 (pd-1) / ligando de pd-1 (pd-l1) y pd-l1 / cd80
AR091424A1 (es) Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr)
AR124117A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR094313A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR097571A1 (es) Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa
AR092742A1 (es) Piridinonas antifibroticas
AR088535A1 (es) Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR088760A1 (es) Derivados de pirrolopirimidina y purina
AR099824A1 (es) Compuestos bicíclicos
AR103561A1 (es) Fenilpiridinas herbicidas
AR099023A1 (es) Pirazolil-heteroarilamidas como agentes plaguicidas
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100975A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR106604A1 (es) Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico
AR100418A1 (es) Compuestos y composiciones para inducir condrogénesis
AR088328A1 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes
AR092347A1 (es) Derivados de azaindol

Legal Events

Date Code Title Description
FB Suspension of granting procedure